Welcome to our dedicated page for Processa Pharmaceuticals SEC filings (Ticker: PCSA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Processa Pharmaceuticals filings document formal 8-K and amended 8-K disclosures for a clinical-stage biopharmaceutical issuer. The records cover material events involving licensing and term-sheet matters, Nasdaq listing compliance, executive-officer status changes and compensatory arrangements, and shareholder-vote reporting.
The company's filings also describe capital-structure and charter actions, including amendments to its certificate of incorporation, authorized-share changes, reverse stock split mechanics, common-stock rights and related governance approvals. These disclosures frame Processa's public-company status, equity structure and corporate governance alongside its development-stage pharmaceutical business.
Processa Pharmaceuticals director and Pres. Research & Development David Young reported an open-market purchase of 1,545 shares of common stock at $2.97 per share on April 15, 2026. After this trade, he holds 12,107 shares directly, plus indirect holdings of 1,242 shares via the Young-Plaisance Revocable Trust, 432 shares via family entities, and 742 shares via CorLyst, LLC.
Processa Pharmaceuticals, Inc. Chief Executive Officer George K. Ng bought additional company stock in the open market. He purchased 1,843 shares of common stock at $2.97 per share, bringing his directly held position to 5,492 shares. The filing also lists indirect holdings of 3,488 shares held under "George Ng IRRA FOB George Ng" and 800 shares held through the "Ng Cha Family Trust," showing both personal and related-entity ownership of Processa common stock.
Processa Pharmaceuticals, Inc. Chief Business - Strategy Officer Patrick Lin bought common stock in the open market. On April 15, 2026, he purchased 1,369 shares of Processa common stock at $2.97 per share. After this transaction, he directly holds 4,725 shares and indirectly holds 1,740 shares through the Lin Family Trust dated February 4, 2024.
Processa Pharmaceuticals Chief Administrative Officer Wendy Guy purchased 1,583 shares of common stock in an open-market transaction at $2.97 per share. After this purchase, she holds 4,693 shares directly and 333 shares indirectly through CorLyst, LLC.
Processa Pharmaceuticals, Inc. Chief Development Officer Sian Bigora reported an open-market purchase of 1,799 shares of common stock at $2.97 per share on April 15, 2026. Following this trade, Bigora directly holds 5,510 common shares and has indirect ownership of 267 shares through CorLyst, LLC.
Processa Pharmaceuticals, Inc. Chief Financial Officer Russell Skibsted reported an open-market purchase of company shares. On April 15, 2026, he bought 1,984 shares of Common Stock at $2.97 per share in a direct ownership transaction, bringing his directly held stake to 4,308 shares.
Processa Pharmaceuticals director Neal James R reported an open-market purchase of the company’s Common Stock. On March 31, 2026, he bought 789 shares at a price of $2.535 per share, bringing his direct ownership to 818 shares after the transaction, indicating a small, routine insider buy.
Processa Pharmaceuticals Pres. of Research & Development David Young bought 1,810 shares of common stock in an open-market purchase at $2.535 per share. After this trade, he directly holds 10,562 shares and has additional indirect holdings through the Young-Plaisance Revocable Trust, family entities, and CorLyst, LLC.
Processa Pharmaceuticals, Inc. Chief Financial Officer Russell Skibsted reported an open-market purchase of company stock. He bought 2,324 shares of Common Stock at a price of $2.535 per share on March 31, 2026, and now directly holds 2,324 shares following this transaction.
Processa Pharmaceuticals director Geraldine Pannu reported an open-market purchase of Common Stock. On March 31, 2026, she bought 2,072 shares at $2.535 per share, bringing her direct holdings to 2,188 shares. This was a straightforward open-market buy with no derivatives involved.